Form 4: Kura Oncology Director Carol Schafer Granted 28,500 Stock Options

Kura Oncology, Inc. Director Carol Schafer was granted 28,500 stock options with an exercise price of $6.57, vesting in one year.

Summary

• Carol Schafer, a Director of Kura Oncology, Inc. (KURA), was granted 28,500 options to purchase common stock.
• The options have an exercise price of $6.57 per share.
• These options were granted on June 5, 2025, and will vest in full on the one-year anniversary of the grant date, which is June 5, 2026.
• The options are set to expire on June 4, 2035.
• Following this transaction, Ms. Schafer beneficially owns 28,500 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event as it aligns the director's financial interests with the long-term performance of the company and shareholder value. It is a standard and expected compensation practice, reflecting normal corporate governance.

Positives

• The grant of 28,500 stock options to Director Carol Schafer aligns her interests with those of shareholders, incentivizing long-term performance and value creation.
• The options have a 10-year expiration date (June 4, 2035), providing a substantial window for potential value realization.

Negatives

• NA

Risks

• NA

Future Outlook

This Form 4 filing details a compensation event for a director and does not provide specific forward-looking statements or guidance regarding the company's operational or financial performance.

Management Comments

• NA

Industry Context

The grant of stock options to directors is a common and standard equity compensation practice within publicly traded companies, particularly in the biotechnology sector, aimed at attracting and retaining qualified board members and aligning their long-term interests with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options as a component of director compensation is a widely adopted practice across industries, including biotechnology, to incentivize long-term performance and align interests with shareholders.
• The exercise price of $6.57 is typical for 'at-the-money' option grants, where the exercise price is set at the market price of the underlying stock on the grant date, a standard industry practice.
• The 10-year expiration period for the options is also a common duration for such equity grants, providing ample time for the options to potentially become in-the-money.

Legal Proceedings

• NA

Related Party Transactions

• The grant of stock options to Director Carol Schafer constitutes a related party transaction, which is a standard component of director compensation packages and is disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial incentives with the company's long-term stock performance, potentially benefiting shareholders through improved governance and strategic decision-making.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The 28,500 stock options granted to Carol Schafer will vest in full on June 5, 2026.

Key Dates

Recommendation

Keywords

Kura Oncology, KURA, stock options, director compensation, SEC Form 4, beneficial ownership, equity grant, insider transaction